Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) has announced key details regarding the spin-off of its diabetes care business, Embecta Corp.. Shareholders of BD as of March 22, 2022 will receive one share of Embecta for every five shares of BD held. 'When issued' trading of Embecta is set to commence on March 21, 2022, under ticker EMBCV, with 'regular way' trading starting on April 1, 2022 under EMBC. The transaction is expected to be tax-free. BD shareholders should consult tax advisers for implications of this spin-off.
BD (Becton, Dickinson and Company) announced that Morgan Stanley has initiated cash tender offers for various notes, totaling a maximum combined purchase price of $200,000,000. The offers include multiple series of notes with varying acceptance priority levels and offer details, including early tender premiums. The offers are scheduled to expire on April 12, 2022, with an early tender date of March 29, 2022. Holders of the notes must tender by these deadlines to receive maximum consideration. The company emphasizes the offers' conditions based on the successful completion of a financing transaction.
BD (Becton, Dickinson and Company) has appointed William "Bill" Brown to its board of directors effective February 28, 2022. Brown, an experienced executive, is currently the executive chair of L3Harris Technologies with $18 billion in annual revenue. He previously served as chair and CEO of L3Harris from July 2019 to June 2021. BD's chairman, Tom Polen, expressed confidence in Brown's leadership skills to support the company's BD2025 strategy aimed at long-term stakeholder value. Having degrees in engineering and an MBA, Brown also holds several board positions.
BD (Becton, Dickinson and Company) will present virtually at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:50 a.m. ET. The event is accessible via a live webcast on the BD investor relations website, and a replay will be available afterward. BD, a leading global medical technology company, focuses on enhancing health care through innovative solutions. With a workforce of approximately 75,000, the company supports health care providers in improving safety and efficiency in patient care.
BD (Becton, Dickinson and Company) has appointed Shana Neal as the new chief people officer, effective April 4, 2022. Neal, who previously held various HR positions at BD from 2005 to 2018, will oversee global HR functions, including Talent Acquisition, Total Rewards, and Diversity initiatives. She replaces Betty Larson, who is transitioning to a new role in the healthcare sector. BD's CEO Tom Polen expressed confidence in Neal's leadership skills and industry knowledge as essential for advancing BD's 2025 strategy and enhancing stakeholder value.
BD (Becton, Dickinson and Company) announced that its diabetes care business, embecta, will spin off on April 1, 2022. To prepare investors, embecta will host a virtual Investor Event on March 7, 2022, starting at 8 a.m. Eastern Time. Presenters include CEO Dev Kurdikar and CFO Jake Elguicze, discussing the company's products, market opportunities, and financial strategies. A Q&A session will follow. More details and a link to the event are available on BD's investor webpage, with a replay accessible post-event.
BD (Becton, Dickinson and Company) reported Q1 FY2022 results with revenues of $4,995 million, down 6% from the previous year. Base revenues rose 8.1%, driven by strong performance in BD Medical, which grew 6% to $2,397 million. However, the BD Life Sciences segment saw a significant decline of 25% due to lower COVID-19 testing revenues. The company raised its FY2022 revenue guidance to $19.55-$19.75 billion and adjusted EPS to $12.80-$13.00. BD continues to focus on innovation, M&A, and ESG initiatives, while also navigating currency headwinds.
On February 1, 2022, BD (Becton, Dickinson and Company) announced its board of directors approved the spinoff of its diabetes care business, set to become Embecta Corp. The spinoff will take effect on April 1, 2022, with BD shareholders receiving one share of Embecta stock for every five shares of BD owned by March 22, 2022. The move aims to sharpen BD's focus on its core growth strategies and enhance Embecta's capacity for capital attraction and innovation in diabetes management. The IRS has deemed the transaction tax-free for U.S. federal income tax purposes.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
